SCHEMBL6882976

SCHEMBL6882976

C(=Cc1ccccc1[Si](c1ccccc1C=Cc1ccccc1)(c1ccccc1C=Cc1ccccc1)c1ccccc1C=Cc1ccccc1)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 5/20 0.54
TRPA1 O75762 2/20 0.54
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAOB P27338 2/20 0.44
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
CYP19A1 P11511 1/20 0.43
MAOA P21397 1/20 0.43
DHFR P00374 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
ATP4A P20648 2/20 0.41
ATP4B P51164 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6882972 1.00 NFE2L2 (0.54) NFE2L2TRPA1MEN1KMT2AMAOB
SCHEMBL7187276 0.83 TRPA1 (0.55) NFE2L2TRPA1MEN1KMT2AMAOB
SCHEMBL44502 0.80 NFE2L2 (0.68) NFE2L2TRPA1MEN1KMT2AMAOB
SCHEMBL6360540 0.80 NFE2L2 (0.68) NFE2L2TRPA1MEN1KMT2AMAOB
SCHEMBL5411617 0.80 NFE2L2 (0.68) NFE2L2TRPA1MEN1KMT2AMAOB
SCHEMBL44503 0.80 NFE2L2 (0.68) NFE2L2TRPA1MEN1KMT2AMAOB
SCHEMBL9540538 0.80 NFE2L2 (0.68) NFE2L2TRPA1MEN1KMT2AMAOB
(Z)-1,2-Diphenylethene SCHEMBL7653143 0.80 NFE2L2 (0.68) NFE2L2TRPA1MEN1KMT2AMAOB
(Z)-1,2-Diphenylethene SCHEMBL7653150 0.80 NFE2L2 (0.68) NFE2L2TRPA1MEN1KMT2AMAOB
SCHEMBL7187435 0.79 TRPA1 (0.52) NFE2L2TRPA1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030055278-A1 Soluble tetrahedral compounds for use in electroluminescent devices NATIONAL SCIENCE FOUNDATION 2003-03-20 US claimed
WO-2001083410-A1 SOLUBLE TETRAHEDRAL COMPOUNDS FOR USE IN ELECTROLUMINESCENT DEVICES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2001-11-08 WO claimed
US-6824890-B2 TOPOLOGICAL STRATEGY FOR DESIGNING AMORPHOUS MOLECULAR SOLIDS FOR FORMING THIN FILMS IN OPTOELECTRONIC DEVICES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2004-11-30 US disclosed
US-20030055278-A1 Soluble tetrahedral compounds for use in electroluminescent devices NATIONAL SCIENCE FOUNDATION 2003-03-20 US disclosed
WO-2001083410-A1 SOLUBLE TETRAHEDRAL COMPOUNDS FOR USE IN ELECTROLUMINESCENT DEVICES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055278-A1 Soluble tetrahedral compounds for use in electroluminescent devices PAX3, EPCAM, PAXBP1 NFE2L2 2377/4885TRPA1 463/4885MEN1 3974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.